Magnesium Sulfate

+ 7 more variants

• Hypotension (Low Blood Pressure): This can cause lightheadedness or dizziness upon standing.
• Nausea and Vomiting: Often associated with the rapid administration of the loading dose.
• Headache: A dull or throbbing sensation.
• Muscle Weakness: A general feeling of heaviness in the limbs.
• Diarrhea: This is the intended effect when used as a laxative but may be an unwanted side effect when used for other indications.

• Hypocalcemia: Magnesium can suppress parathyroid hormone, leading to low calcium levels in the blood, which may cause muscle cramps or tingling in the extremities.
• Visual Disturbances: Blurred or double vision (diplopia).
• Confusion: Disorientation or difficulty concentrating.

> Warning: Stop taking Magnesium Sulfate Heptahydrate and call your doctor immediately if you experience any of these serious symptoms. These are often signs of magnesium toxicity.

• Loss of Deep Tendon Reflexes: If your doctor taps your knee and there is no "kick" response, this is a critical warning sign that magnesium levels are too high.
• Respiratory Paralysis: Difficulty breathing, shortness of breath, or a very slow breathing rate (less than 12 breaths per minute).
• Cardiac Arrhythmias: Feeling like your heart is skipping a beat, racing, or beating too slowly.
• Extreme Hypotension: Fainting or feeling like you are about to pass out.
• Decreased Urine Output (Oliguria): Since magnesium is cleared by the kidneys, a drop in urine production can lead to a rapid, dangerous buildup of the drug in the blood.
• Profound Lethargy: Inability to stay awake or respond to verbal commands.

Magnesium Sulfate Heptahydrate is generally intended for short-term use. Prolonged use (especially beyond 5 to 7 days in pregnant women) has been associated with:

• Fetal Bone Abnormalities: Prolonged in utero exposure can lead to low calcium levels and bone demineralization (thinning) in the newborn.
• Electrolyte Imbalance: Chronic use as a laxative can lead to dependency and significant imbalances in potassium, sodium, and calcium, potentially affecting heart and kidney function.
• Magnesium Accumulation: In patients with undiagnosed mild renal impairment, long-term use can lead to chronic hypermagnesemia, manifesting as persistent fatigue and muscle weakness.

There is currently no FDA black box warning for Magnesium Sulfate Heptahydrate. However, the FDA has issued a Drug Safety Communication warning against the prolonged use (more than 5-7 days) of magnesium sulfate injection for the treatment of preterm labor, as it can lead to low calcium levels and bone problems in the developing fetus.

Report any unusual symptoms to your healthcare provider immediately. Monitoring of serum magnesium levels is the standard of care during high-dose therapy to ensure safety.

During intravenous administration of Magnesium Sulfate Heptahydrate, the following must be monitored at regular intervals (often every 1 to 4 hours):

1. 1Deep Tendon Reflexes (DTRs): Patellar reflexes must be present.
2. 2Respiratory Rate: Must be at least 12 to 16 breaths per minute.
3. 3Urine Output: Must be maintained at a minimum of 25-30 mL per hour.
4. 4Serum Magnesium Levels: The therapeutic range for seizure prevention is typically 4 to 7 mEq/L (4.8 to 8.4 mg/dL).
5. 5Fetal Heart Rate: Continuous monitoring is required when used in pregnant patients.

Magnesium sulfate can cause significant drowsiness, blurred vision, and muscle weakness. Patients receiving this medication should not drive or operate heavy machinery until the effects have completely worn off and they have been cleared by a physician.

Alcohol should be avoided while using magnesium sulfate, particularly when used as an oral laxative. Alcohol can exacerbate the dehydrating effects of the laxative and increase the risk of central nervous system depression, leading to extreme dizziness or confusion.

For oral laxative use, the drug should be discontinued if no bowel movement occurs after use, as this may indicate a more serious underlying condition like a bowel obstruction. For IV use in eclampsia, the medication is typically continued for 24 hours after delivery or 24 hours after the last seizure, then tapered or stopped as per clinical protocol.

> Important: Discuss all your medical conditions, especially kidney disease and neuromuscular disorders, with your healthcare provider before starting Magnesium Sulfate Heptahydrate.

• Tetracycline and Quinolone Antibiotics: Oral magnesium can chelate (bind) to these antibiotics (e.g., doxycycline, ciprofloxacin) in the gut, significantly reducing their absorption and efficacy. These medications should be taken at least 2 hours before or 6 hours after oral magnesium sulfate.
• Bisphosphonates: Oral magnesium can interfere with the absorption of bone-strengthening medications like alendronate. Space doses by at least 2 hours.
• Potassium-Sparing Diuretics: Using magnesium with drugs like spironolactone can lead to increased magnesium levels, as these diuretics may reduce magnesium excretion.

• High-Fat Meals: May slightly delay the transit time of oral magnesium but do not significantly impact the total amount absorbed.
• Dairy Products: High calcium intake from dairy can compete with magnesium for absorption in the intestines. While not usually clinically significant for a single laxative dose, it can matter for long-term supplementation.

• St. John's Wort: May increase the risk of sedation when combined with the CNS-dampening effects of magnesium.
• Calcium Supplements: High doses of oral calcium can reduce the effectiveness of oral magnesium by competing for the same uptake transporters in the small intestine.

• Serum Calcium: Magnesium sulfate may cause a false decrease in serum calcium measurements depending on the laboratory method used.
• Serum Creatinine: High levels of magnesium can interfere with certain colorimetric assays for creatinine, potentially leading to inaccurate assessments of kidney function.

For each major interaction, the management strategy usually involves either spacing the doses, reducing the dosage of the interacting agent, or increasing the frequency of clinical monitoring (e.g., checking reflexes and respiratory rate more often).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter antacids and laxatives.

Relative Contraindications

Conditions requiring a careful risk-benefit analysis include:

• Moderate Renal Impairment: Requires strict dose reduction and frequent lab monitoring.
• Digitalis Toxicity: Magnesium can worsen heart block associated with digitalis, though it is ironically used to treat certain digitalis-induced arrhythmias (like Torsades).
• Hypocalcemia: Because magnesium can further lower calcium levels, existing deficiency must be addressed cautiously.
• Dehydration: When used as a laxative, magnesium sulfate can worsen dehydration and electrolyte depletion.

There is no known cross-sensitivity between Magnesium Sulfate Heptahydrate and other classes of drugs. However, patients who have had a previous hypersensitivity reaction to any magnesium salt (such as magnesium citrate or magnesium oxide) should avoid magnesium sulfate heptahydrate.

> Important: Your healthcare provider will evaluate your complete medical history, including any history of heart disease or kidney problems, before prescribing Magnesium Sulfate Heptahydrate.

• Approved Indications: Used for hypomagnesemia and as a laxative in children over 6. It is also used in the treatment of acute nephritis with hypertension.
• Safety: Children are more susceptible to electrolyte imbalances and dehydration when using osmotic laxatives. Dosing must be strictly weight-based.
• Growth Effects: No long-term effects on growth have been documented with short-term use.

• Renal Risk: The elderly are at significantly higher risk for magnesium toxicity due to the natural age-related decline in GFR.
• Fall Risk: The muscle-relaxant and sedative effects of magnesium increase the risk of falls and fractures in older adults.
• Polypharmacy: Older patients are more likely to be on interacting medications like digoxin or diuretics, necessitating closer monitoring.

• Dose Adjustment: Mandatory for any patient with a creatinine clearance below 60 mL/min.
• Monitoring: Serum magnesium levels should be checked every 2-4 hours. The infusion should be stopped if the serum level exceeds the therapeutic range or if reflexes disappear.

No specific dose adjustments are needed for isolated liver disease, but clinicians must be alert for secondary renal issues (hepatorenal syndrome) that would impair magnesium clearance.

> Important: Special populations require individualized medical assessment and often more frequent laboratory monitoring to ensure safety.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (IV); 30-40% (Oral) |

| Protein Binding | ~40% (to Albumin) |

| Half-life | 4-6 hours (Normal Renal Function) |

| Tmax | Immediate (IV); 1-2 hours (IM) |

| Metabolism | None (Inorganic Salt) |

| Excretion | Renal (>90% of absorbed dose) |

• Molecular Formula: MgSO4·7H2O
• Molecular Weight: 246.47 g/mol
• Solubility: Highly soluble in water (approx. 710 g/L at 20°C); slightly soluble in alcohol.
• Structure: It consists of a magnesium cation (Mg2+) and a sulfate anion (SO4 2-) associated with seven molecules of water of crystallization. It appears as small, colorless, needle-like crystals.

Magnesium Sulfate Heptahydrate is classified as an electrolyte replenisher, an anticonvulsant, and an osmotic laxative. In the context of the EPC system, it is also listed under Non-Standardized Food Allergenic Extracts and Lipid Emulsions when used as a component in those specialized medical products.